These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17523002)

  • 1. Simultaneous estradiol and levonorgestrel transdermal delivery from a 7-day patch: in vitro and in vivo drug deliveries of three formulations.
    Harrison LI; Zurth C; Gunther C; Karara AH; Melikian A; Lipp R
    Drug Dev Ind Pharm; 2007 Apr; 33(4):373-80. PubMed ID: 17523002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of continuous once-a-week combination 17β-Estradiol/Low- or high-dose levonorgestrel transdermal delivery systems in postmenopausal women.
    Karara AH; Harrison LI; Melikian AP; Poola N; Morrison D; Bourg D; Bourg L; Zurth C
    J Clin Pharmacol; 2014 May; 54(5):520-7. PubMed ID: 24474034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin sensitivity during postmenopausal hormone replacement with transdermal estradiol and intrauterine levonorgestrel.
    Raudaskoski T; Tomás C; Laatikainen T
    Acta Obstet Gynecol Scand; 1999 Jul; 78(6):540-5. PubMed ID: 10376866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal dual-controlled delivery of contraceptive drugs: formulation development, in vitro and in vivo evaluations, and clinical performance.
    Chien YW; Chien TY; Bagdon RE; Huang YC; Bierman RH
    Pharm Res; 1989 Dec; 6(12):1000-10. PubMed ID: 2516312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endometrial safety of a transdermal sequential estradiol-levonorgestrel combination.
    Sturdee DW; van de Weijer P; von Holst T
    Climacteric; 2002 Jun; 5(2):170-7. PubMed ID: 12051113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses.
    Antoniou G; Kalogirou D; Karakitsos P; Antoniou D; Kalogirou O; Giannikos L
    Maturitas; 1997 Mar; 26(2):103-11. PubMed ID: 9089559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of estradiol from two matrix transdermal delivery systems: Menorest and Climara.
    Andersson TL; Stehle B; Davidsson B; Höglund P
    Maturitas; 2000 Jan; 34(1):57-64. PubMed ID: 10687883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of in vitro-in vivo correlation (IVIVC) for estradiol transdermal drug delivery systems.
    Yang Y; Manda P; Pavurala N; Khan MA; Krishnaiah YS
    J Control Release; 2015 Jul; 210():58-66. PubMed ID: 25979329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative bioequivalence studies with Estradot and Menorest transdermal systems.
    Hossain M; Quebe-Fehling E; Sergejew T; Schmidt G; Skerjanec A; Cohen A; Krinsky L; Ibarra de Palacios P
    Maturitas; 2003 Nov; 46(3):187-98. PubMed ID: 14585521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of site of application on the transcutaneous absorption of 17-beta estradiol from a transdermal delivery system (Climara).
    Taggart W; Dandekar K; Ellman H; Notelovitz M
    Menopause; 2000; 7(5):364-9. PubMed ID: 10993035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of bioequivalence of two 7-day 17beta-estradiol transdermal delivery systems by anatomical site.
    Harrison LL; Harari D
    J Clin Pharmacol; 2002 Oct; 42(10):1134-41. PubMed ID: 12362928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estradiol and levonorgestrel: effects on bleeding pattern when administered in a sequential combined regimen with a new transdermal patch.
    van de Weijer PH; Sturdee DW; von Holst T
    Climacteric; 2002 Mar; 5(1):36-44. PubMed ID: 11974558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 17beta-estradiol matrixpatch removal and reapplication in postmenopausal women: theoretical predictions with an oscillating diffusion coefficient model.
    Rohr UD; Saeger-Lorenz K
    J Pharm Sci; 2002 Mar; 91(3):822-44. PubMed ID: 11920768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch.
    Järvinen A; Bäckström A; Elfström C; Viitanen A
    Maturitas; 2001 Apr; 38(2):189-96. PubMed ID: 11306208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
    Rohr UD; Nauert C; Stehle B
    Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara.
    Buch A; Shen L; Kelly S; Sahota R; Brezovic C; Bixler C; Powell J
    Menopause; 1998; 5(2):107-12. PubMed ID: 9689205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability and pharmacodynamics of two 10-mg estradiol valerate depot formulations following IM single dose administration in healthy postmenopausal volunteers.
    Schug BS; Donath F; Blume HH
    Int J Clin Pharmacol Ther; 2012 Feb; 50(2):100-17. PubMed ID: 22257576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group.
    Archer DF; Furst K; Tipping D; Dain MP; Vandepol C
    Obstet Gynecol; 1999 Oct; 94(4):498-503. PubMed ID: 10511348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.